The current treatments of liver cancer in China are mainly comprehensive\ntreatment and systematic treatment, with poor therapeutic effect and high\nrecurrence rate and metastasis rate. The existence of immunosuppressive microenvironment\nis an important reason for liver tumor cells to escape from\nthe host immune system, and also an important basis for the occurrence and\ndevelopment of liver cancer. With the recent transformation of the target of\ntumor therapy from tumor cells to tumor cell immune microenvironment,\nimmunotherapy has emerged quietly. It is a new strategy for the treatment of\nhepatocellular carcinoma to improve the immune attack on tumor cells by\nchanging the immunosuppressive environment of hepatocellular carcinoma\ncells. Immune checkpoint is the main mechanism by which liver cancer cells\nescape the host immune system. PD-1/PDL-1 and CTLA-4 are targeted immunocheckpoint\ninhibitors, which have shown good therapeutic effects and\napplication prospects in the clinical treatment of HCC. This article reviews\nthe latest advances in immunocheckpoint inhibitors in the immunotherapy of\nhepatocellular carcinoma.
Loading....